Apricoxib
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C19H20N2O3S |
| Molar mass | 356.44g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Apricoxibis an experimental anticancer drug andnonsteroidal anti-inflammatory drug(NSAID).[1]It is aCOX-2 inhibitorwhich is intended to improve standard therapy response in molecularly-defined models ofpancreatic cancer.[2]It was also studied in clinical trials fornon-small-cell lung cancer.[3]Development was abandoned in 2015 due to poor clinical trial results.[4]
See also
[edit]References
[edit]- ^"Apricoxib (Code C74021)".NCI Thesaurus.National Cancer Institute.
- ^Kirane A, Toombs JE, Ostapoff K, Carbon JG, Zaknoen S, Braunfeld J, et al. (September 2012)."Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer".Clinical Cancer Research.18(18): 5031–42.doi:10.1158/1078-0432.CCR-12-0453.PMC3777527.PMID22829202.
- ^Edelman MJ, Tan MT, Fidler MJ, Sanborn RE, Otterson G, Sequist LV, et al. (January 2015)."Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer".Journal of Clinical Oncology.33(2): 189–94.doi:10.1200/JCO.2014.55.5789.PMC4890680.PMID25452446.
- ^"Apricoxib".Adis Insight.Springer Nature Switzerland AG.
 | Thisdrugarticle relating to themusculoskeletal systemis astub.You can help Wikipedia byexpanding it. |